Inivata Risk Report

⚖️ Legal & Regulatory

Inivata had certain legal challenges concerning intellectual property. Patent disputes are significant risks in the biotechnology field, and staying informed of ongoing litigation can be crucial for stakeholders. Recent developments highlight that effective intellectual property management remains a priority to ensure robust protection against competitors.

• NeoGenomics, which acquired Inivata, plans to fight an unfavorable ruling in a patent case with a competitor as of 🗓 2023-12-28.

📜 Innovation & R&D

Innovation remains a core component of Inivata's strategy, particularly concerning its liquid biopsy technology. The company is advancing its Radar™ assay system, a critical component in the personalized cancer treatment landscape, maintaining a competitive edge with designations and regulatory progress.

• The Radar™ assay system received CE Mark approval and was submitted for US reimbursement through the MolDx program as of 🗓 2022-01-11.
• Inivata's Radar assay achieved a significant milestone of receiving expedited regulatory pathway designation from the FDA on 🗓 2021-03-10, continuing a string of advancements initiated with a breakthrough device designation on 🗓 2021-03-09.